This Medical Affairs webinar teaches attendees to build a framework that enables MSL insights to inform Medical strategy at both the local and global level.
This Medical Affairs webinar assembles leading biopharma industry experts to discuss preparing your organization for digital transformation.
This webinar describes the NeuroLeadership Institute’s SCARF model (Status, Certainty, Autonomy, Relatedness, Fairness) and its application to the practice of Medical Affairs
This MAPS webinar presents an overview of the current and near term Digital Therapeutics landscape and details real-world applications of Digital Therapeutics to illustrate potential in driving transformation of clinical practices to improve patient outcomes.
What is company and medical affairs led education and how it is perceived by audience? What are the different perspectives existing among regulators, Pharma and agencies? What is the potential for disease state medical education by medical affairs?
OBJECTIVES: Identify the major trends and drivers towards digital transformation and drive Medical Affairs towards a digital future.
Through this course you will recognize terms such as artificial intelligence (AI), machine learning (ML), deep learning, and neural networks to arrive at best decisions and insights needed for success.
As a result of the global COVID-19 outbreak, field teams are no longer able to visit HCPs face-to-face. During this Webinar, we will explore the skills and challenges around effective remote engagement and share hints and tips to help you access, engage and follow-up with HCPs remotely.
Join this Webinar to better understand contemporary practices for data generation strategies; describe how to design data generation strategies, implementation of the strategies, and how to communicate new evidence; and describe how real-world evidence may be utilized to support product value including regulatory label change.
In this session, you will hear “insider tips” from three senior-level Medical Affairs leaders from leading multinational biopharma companies.